A post hoc mediation analysis of the SURMOUNT-1 to -4 trials found that gastrointestinal adverse events contributed only slightly (up to 3.1%) to tirzepatide-associated weight reduction, which was similar regardless of nausea. PICO summary and expert commentary.
Browsing: Obesity & Weight Management
A 10-week whole-food plant-based community programme produced significant between-group weight loss but no significant glycaemic or lipid change in this small New Zealand RCT. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.
A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
A first-in-human phase 1 trial of oral amycretin in overweight or obesity found it safe and tolerable, with dose-dependent gastrointestinal effects and exploratory weight loss. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
A secondary analysis of a weight-loss-maintenance RCT found that low-calorie-diet weight loss raised serum 25(OH)D in both sexes, but further loss and low baseline vitamin D tracked with maintenance only in women. PICO summary and expert commentary.
A secondary patient-reported-outcomes analysis of the SURMOUNT-1 phase 3 trial finds tirzepatide improved health-related quality of life versus placebo in adults with obesity, with larger gains at greater weight loss. PICO summary and expert commentary.
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 1 first-in-human study of the oral GLP-1 receptor agonist ECC5004/AZD5004 in healthy volunteers and T2DM patients found it well tolerated with early dose-dependent glucose and weight signals. PICO summary and expert commentary.